Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Vitamin D increases glucocorticoid efficacy via inhibition of mTORC1 in experimental models of multiple sclerosis.

Hoepner R, Bagnoud M, Pistor M, Salmen A, Briner M, Synn H, Schrewe L, Guse K, Ahmadi F, Demir S, Laverick L, Gresle M, Worley P, Reichardt HM, Butzkueven H, Gold R, Metz I, Lühder F, Chan A.

Acta Neuropathol. 2019 Sep;138(3):443-456. doi: 10.1007/s00401-019-02018-8. Epub 2019 Apr 27.

2.

Disease-Modifying Osteoarthritis Treatment With Interleukin-1 Receptor Antagonist Gene Therapy in Small and Large Animal Models.

Nixon AJ, Grol MW, Lang HM, Ruan MZC, Stone A, Begum L, Chen Y, Dawson B, Gannon F, Plutizki S, Lee BHL, Guse K.

Arthritis Rheumatol. 2018 Nov;70(11):1757-1768. doi: 10.1002/art.40668. Epub 2018 Sep 10.

PMID:
30044894
3.

Teriflunomide and monomethylfumarate target HIV-induced neuroinflammation and neurotoxicity.

Ambrosius B, Faissner S, Guse K, von Lehe M, Grunwald T, Gold R, Grewe B, Chan A.

J Neuroinflammation. 2017 Mar 11;14(1):51. doi: 10.1186/s12974-017-0829-2.

4.

Expression of DAI by an oncolytic vaccinia virus boosts the immunogenicity of the virus and enhances antitumor immunity.

Hirvinen M, Capasso C, Guse K, Garofalo M, Vitale A, Ahonen M, Kuryk L, Vähä-Koskela M, Hemminki A, Fortino V, Greco D, Cerullo V.

Mol Ther Oncolytics. 2016 Mar 23;3:16002. doi: 10.1038/mto.2016.2. eCollection 2016.

5.

Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for Treatment of HER2-Positive Cancer.

Liikanen I, Tähtinen S, Guse K, Gutmann T, Savola P, Oksanen M, Kanerva A, Hemminki A.

Mol Cancer Ther. 2016 Sep;15(9):2259-69. doi: 10.1158/1535-7163.MCT-15-0819. Epub 2016 Jul 25.

6.

MGMT Promoter Methylation and BRAF V600E Mutations Are Helpful Markers to Discriminate Pleomorphic Xanthoastrocytoma from Giant Cell Glioblastoma.

Lohkamp LN, Schinz M, Gehlhaar C, Guse K, Thomale UW, Vajkoczy P, Heppner FL, Koch A.

PLoS One. 2016 Jun 2;11(6):e0156422. doi: 10.1371/journal.pone.0156422. eCollection 2016.

7.

Genome wide DNA copy number analysis in cholangiocarcinoma using high resolution molecular inversion probe single nucleotide polymorphism assay.

Arnold A, Bahra M, Lenze D, Bradtmöller M, Guse K, Gehlhaar C, Bläker H, Heppner FL, Koch A.

Exp Mol Pathol. 2015 Oct;99(2):344-53. doi: 10.1016/j.yexmp.2015.08.003. Epub 2015 Aug 8.

PMID:
26260902
8.

Incomplete but infectious vaccinia virions are produced in the absence of oncolysis in feline SCCF1 cells.

Parviainen S, Autio K, Vähä-Koskela M, Guse K, Pesonen S, Rosol TJ, Zhao F, Hemminki A.

PLoS One. 2015 Mar 23;10(3):e0120496. doi: 10.1371/journal.pone.0120496. eCollection 2015.

9.

Oncolytic adenovirus and doxorubicin-based chemotherapy results in synergistic antitumor activity against soft-tissue sarcoma.

Siurala M, Bramante S, Vassilev L, Hirvinen M, Parviainen S, Tähtinen S, Guse K, Cerullo V, Kanerva A, Kipar A, Vähä-Koskela M, Hemminki A.

Int J Cancer. 2015 Feb 15;136(4):945-54. doi: 10.1002/ijc.29048. Epub 2014 Jul 3.

10.

Hedgehog pathway as a potential treatment target in human cholangiocarcinoma.

Riedlinger D, Bahra M, Boas-Knoop S, Lippert S, Bradtmöller M, Guse K, Seehofer D, Bova R, Sauer IM, Neuhaus P, Koch A, Kamphues C.

J Hepatobiliary Pancreat Sci. 2014 Aug;21(8):607-15. doi: 10.1002/jhbp.107. Epub 2014 Apr 15.

PMID:
24733827
11.

Safety and biodistribution of a double-deleted oncolytic vaccinia virus encoding CD40 ligand in laboratory Beagles.

Autio K, Knuuttila A, Kipar A, Pesonen S, Guse K, Parviainen S, Rajamäki M, Laitinen-Vapaavuori O, Vähä-Koskela M, Kanerva A, Hemminki A.

Mol Ther Oncolytics. 2014 Dec 10;1:14002. doi: 10.1038/mto.2014.2. eCollection 2014.

12.

Proteoglycan 4 expression protects against the development of osteoarthritis.

Ruan MZ, Erez A, Guse K, Dawson B, Bertin T, Chen Y, Jiang MM, Yustein J, Gannon F, Lee BH.

Sci Transl Med. 2013 Mar 13;5(176):176ra34. doi: 10.1126/scitranslmed.3005409.

13.

Interventions using new digital media to improve adolescent sexual health: a systematic review.

Guse K, Levine D, Martins S, Lira A, Gaarde J, Westmorland W, Gilliam M.

J Adolesc Health. 2012 Dec;51(6):535-43. doi: 10.1016/j.jadohealth.2012.03.014. Epub 2012 May 5. Review.

PMID:
23174462
14.

Capsid-modified adenoviral vectors for improved muscle-directed gene therapy.

Guse K, Suzuki M, Sule G, Bertin TK, Tyynismaa H, Ahola-Erkkilä S, Palmer D, Suomalainen A, Ng P, Cerullo V, Hemminki A, Lee B.

Hum Gene Ther. 2012 Oct;23(10):1065-70. doi: 10.1089/hum.2012.003. Epub 2012 Aug 13.

15.

Nitric-oxide supplementation for treatment of long-term complications in argininosuccinic aciduria.

Nagamani SC, Campeau PM, Shchelochkov OA, Premkumar MH, Guse K, Brunetti-Pierri N, Chen Y, Sun Q, Tang Y, Palmer D, Reddy AK, Li L, Slesnick TC, Feig DI, Caudle S, Harrison D, Salviati L, Marini JC, Bryan NS, Erez A, Lee B.

Am J Hum Genet. 2012 May 4;90(5):836-46. doi: 10.1016/j.ajhg.2012.03.018. Epub 2012 Apr 26.

16.

Cytokine-conditioned dendritic cells induce humoral tolerance to protein therapy in mice.

Sule G, Suzuki M, Guse K, Cela R, Rodgers JR, Lee B.

Hum Gene Ther. 2012 Jul;23(7):769-80. doi: 10.1089/hum.2011.225. Epub 2012 May 11.

17.

Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4.

Dias JD, Hemminki O, Diaconu I, Hirvinen M, Bonetti A, Guse K, Escutenaire S, Kanerva A, Pesonen S, Löskog A, Cerullo V, Hemminki A.

Gene Ther. 2012 Oct;19(10):988-98. doi: 10.1038/gt.2011.176. Epub 2011 Nov 10.

PMID:
22071969
18.

Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors.

Pesonen S, Diaconu I, Cerullo V, Escutenaire S, Raki M, Kangasniemi L, Nokisalmi P, Dotti G, Guse K, Laasonen L, Partanen K, Karli E, Haavisto E, Oksanen M, Karioja-Kallio A, Hannuksela P, Holm SL, Kauppinen S, Joensuu T, Kanerva A, Hemminki A.

Int J Cancer. 2012 Apr 15;130(8):1937-47. doi: 10.1002/ijc.26216. Epub 2011 Aug 8.

19.

Oncolytic vaccinia virus for the treatment of cancer.

Guse K, Cerullo V, Hemminki A.

Expert Opin Biol Ther. 2011 May;11(5):595-608. doi: 10.1517/14712598.2011.558838. Epub 2011 Feb 22. Review.

PMID:
21338330
20.

Oncolytic adenovirus based on serotype 3.

Hemminki O, Bauerschmitz G, Hemmi S, Lavilla-Alonso S, Diaconu I, Guse K, Koski A, Desmond RA, Lappalainen M, Kanerva A, Cerullo V, Pesonen S, Hemminki A.

Cancer Gene Ther. 2011 Apr;18(4):288-96. doi: 10.1038/cgt.2010.79. Epub 2010 Dec 24.

21.

Monozygotic twins with neurofibromatosis type 1 (NF1) display differences in methylation of NF1 gene promoter elements, 5' untranslated region, exon and intron 1.

Harder A, Titze S, Herbst L, Harder T, Guse K, Tinschert S, Kaufmann D, Rosenbaum T, Mautner VF, Windt E, Wahlländer-Danek U, Wimmer K, Mundlos S, Peters H.

Twin Res Hum Genet. 2010 Dec;13(6):582-94. doi: 10.1375/twin.13.6.582.

PMID:
21142935
22.

Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF.

Koski A, Kangasniemi L, Escutenaire S, Pesonen S, Cerullo V, Diaconu I, Nokisalmi P, Raki M, Rajecki M, Guse K, Ranki T, Oksanen M, Holm SL, Haavisto E, Karioja-Kallio A, Laasonen L, Partanen K, Ugolini M, Helminen A, Karli E, Hannuksela P, Pesonen S, Joensuu T, Kanerva A, Hemminki A.

Mol Ther. 2010 Oct;18(10):1874-84. doi: 10.1038/mt.2010.161. Epub 2010 Jul 27.

23.

Mitochondrial myopathy induces a starvation-like response.

Tyynismaa H, Carroll CJ, Raimundo N, Ahola-Erkkilä S, Wenz T, Ruhanen H, Guse K, Hemminki A, Peltola-Mjøsund KE, Tulkki V, Oresic M, Moraes CT, Pietiläinen K, Hovatta I, Suomalainen A.

Hum Mol Genet. 2010 Oct 15;19(20):3948-58. doi: 10.1093/hmg/ddq310. Epub 2010 Jul 23.

PMID:
20656789
24.

Oncolytic adenovirus ICOVIR-7 in patients with advanced and refractory solid tumors.

Nokisalmi P, Pesonen S, Escutenaire S, Särkioja M, Raki M, Cerullo V, Laasonen L, Alemany R, Rojas J, Cascallo M, Guse K, Rajecki M, Kangasniemi L, Haavisto E, Karioja-Kallio A, Hannuksela P, Oksanen M, Kanerva A, Joensuu T, Ahtiainen L, Hemminki A.

Clin Cancer Res. 2010 Jun 1;16(11):3035-43. doi: 10.1158/1078-0432.CCR-09-3167. Epub 2010 May 25.

25.

Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients.

Cerullo V, Pesonen S, Diaconu I, Escutenaire S, Arstila PT, Ugolini M, Nokisalmi P, Raki M, Laasonen L, Särkioja M, Rajecki M, Kangasniemi L, Guse K, Helminen A, Ahtiainen L, Ristimäki A, Räisänen-Sokolowski A, Haavisto E, Oksanen M, Karli E, Karioja-Kallio A, Holm SL, Kouri M, Joensuu T, Kanerva A, Hemminki A.

Cancer Res. 2010 Jun 1;70(11):4297-309. doi: 10.1158/0008-5472.CAN-09-3567. Epub 2010 May 18.

26.

Targeted chemotherapy for head and neck cancer with a chimeric oncolytic adenovirus coding for bifunctional suicide protein FCU1.

Dias JD, Liikanen I, Guse K, Foloppe J, Sloniecka M, Diaconu I, Rantanen V, Eriksson M, Hakkarainen T, Lusky M, Erbs P, Escutenaire S, Kanerva A, Pesonen S, Cerullo V, Hemminki A.

Clin Cancer Res. 2010 May 1;16(9):2540-9. doi: 10.1158/1078-0432.CCR-09-2974. Epub 2010 Apr 13.

27.

Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors.

Pesonen S, Nokisalmi P, Escutenaire S, Särkioja M, Raki M, Cerullo V, Kangasniemi L, Laasonen L, Ribacka C, Guse K, Haavisto E, Oksanen M, Rajecki M, Helminen A, Ristimäki A, Karioja-Kallio A, Karli E, Kantola T, Bauerschmitz G, Kanerva A, Joensuu T, Hemminki A.

Gene Ther. 2010 Jul;17(7):892-904. doi: 10.1038/gt.2010.17. Epub 2010 Mar 18.

PMID:
20237509
28.

Cancer gene therapy with oncolytic adenoviruses.

Guse K, Hemminki A.

J BUON. 2009 Sep;14 Suppl 1:S7-15. Review.

29.

Multimodal approach using oncolytic adenovirus, cetuximab, chemotherapy and radiotherapy in HNSCC low passage tumour cell cultures.

Dias JD, Guse K, Nokisalmi P, Eriksson M, Chen DT, Diaconu I, Tenhunen M, Liikanen I, Grénman R, Savontaus M, Pesonen S, Cerullo V, Hemminki A.

Eur J Cancer. 2010 Feb;46(3):625-35. doi: 10.1016/j.ejca.2009.11.005. Epub 2009 Dec 16.

PMID:
20006487
30.

Antiangiogenic arming of an oncolytic vaccinia virus enhances antitumor efficacy in renal cell cancer models.

Guse K, Sloniecka M, Diaconu I, Ottolino-Perry K, Tang N, Ng C, Le Boeuf F, Bell JC, McCart JA, Ristimäki A, Pesonen S, Cerullo V, Hemminki A.

J Virol. 2010 Jan;84(2):856-66. doi: 10.1128/JVI.00692-09. Epub 2009 Nov 11.

31.

Oncolytic adenovirus treatment of a patient with refractory neuroblastoma.

Pesonen S, Helin H, Nokisalmi P, Escutenaire S, Ribacka C, Sarkioja M, Cerullo V, Guse K, Bauerschmitz G, Laasonen L, Kantola T, Ristimaki A, Rajecki M, Oksanen M, Haavisto E, Kanerva A, Joensuu T, Hemminki A.

Acta Oncol. 2010;49(1):117-9. doi: 10.3109/02841860903071369. No abstract available.

PMID:
19735000
32.

Mre11 inhibition by oncolytic adenovirus associates with autophagy and underlies synergy with ionizing radiation.

Rajecki M, af Hällström T, Hakkarainen T, Nokisalmi P, Hautaniemi S, Nieminen AI, Tenhunen M, Rantanen V, Desmond RA, Chen DT, Guse K, Stenman UH, Gargini R, Kapanen M, Klefström J, Kanerva A, Pesonen S, Ahtiainen L, Hemminki A.

Int J Cancer. 2009 Nov 15;125(10):2441-9. doi: 10.1002/ijc.24608.

33.

Systemic adenoviral gene delivery to orthotopic murine breast tumors with ablation of coagulation factors, thrombocytes and Kupffer cells.

Koski A, Rajecki M, Guse K, Kanerva A, Ristimäki A, Pesonen S, Escutenaire S, Hemminki A.

J Gene Med. 2009 Nov;11(11):966-77. doi: 10.1002/jgm.1373.

PMID:
19670332
34.

Differential MSH2 promoter methylation in blood cells of Neurofibromatosis type 1 (NF1) patients.

Titze S, Peters H, Währisch S, Harder T, Guse K, Buske A, Tinschert S, Harder A.

Eur J Hum Genet. 2010 Jan;18(1):81-7. doi: 10.1038/ejhg.2009.129. Erratum in: Eur J Hum Genet. 2010 Apr;18(4):509.

35.

An integrated cell culture lab on a chip: modular microdevices for cultivation of mammalian cells and delivery into microfluidic microdroplets.

Hufnagel H, Huebner A, Gülch C, Güse K, Abell C, Hollfelder F.

Lab Chip. 2009 Jun 7;9(11):1576-82. doi: 10.1039/b821695a. Epub 2009 Mar 11.

PMID:
19458865
36.

Ad5/3-9HIF-Delta24-VEGFR-1-Ig, an infectivity enhanced, dual-targeted and antiangiogenic oncolytic adenovirus for kidney cancer treatment.

Guse K, Diaconu I, Rajecki M, Sloniecka M, Hakkarainen T, Ristimäki A, Kanerva A, Pesonen S, Hemminki A.

Gene Ther. 2009 Aug;16(8):1009-20. doi: 10.1038/gt.2009.56. Epub 2009 May 14.

PMID:
19440223
37.

Serotype chimeric and fiber-mutated adenovirus Ad5/19p-HIT for targeting renal cancer and untargeting the liver.

Diaconu I, Denby L, Pesonen S, Cerullo V, Bauerschmitz GJ, Guse K, Rajecki M, Dias JD, Taari K, Kanerva A, Baker AH, Hemminki A.

Hum Gene Ther. 2009 Jun;20(6):611-20. doi: 10.1089/hum.2008.108.

PMID:
19239383
38.

Treatment of metastatic renal cancer with capsid-modified oncolytic adenoviruses.

Guse K, Ranki T, Ala-Opas M, Bono P, Särkioja M, Rajecki M, Kanerva A, Hakkarainen T, Hemminki A.

Mol Cancer Ther. 2007 Oct;6(10):2728-36.

39.

Oncolytic adenoviruses kill breast cancer initiating CD44+CD24-/low cells.

Eriksson M, Guse K, Bauerschmitz G, Virkkunen P, Tarkkanen M, Tanner M, Hakkarainen T, Kanerva A, Desmond RA, Pesonen S, Hemminki A.

Mol Ther. 2007 Dec;15(12):2088-93. Epub 2007 Sep 11.

40.

Luciferase imaging for evaluation of oncolytic adenovirus replication in vivo.

Guse K, Dias JD, Bauerschmitz GJ, Hakkarainen T, Aavik E, Ranki T, Pisto T, Särkioja M, Desmond RA, Kanerva A, Hemminki A.

Gene Ther. 2007 Jun;14(11):902-11. Epub 2007 Mar 22.

PMID:
17377596
41.

Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells.

Bauerschmitz GJ, Guse K, Kanerva A, Menzel A, Herrmann I, Desmond RA, Yamamoto M, Nettelbeck DM, Hakkarainen T, Dall P, Curiel DT, Hemminki A.

Mol Ther. 2006 Aug;14(2):164-74. Epub 2006 Mar 31.

Supplemental Content

Support Center